Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults | Zendy

Roeland E. Wasmann | Zendy; Cornelis Smit | Zendy; Rob ter Heine | Zendy; Simon E. Koele | Zendy; Eric P H van Dongen | Zendy; René M J Wiezer | Zendy; David M. Burger | Zendy; Catherijne A. J. Knibbe | Zendy; Roger J. M. Brüggemann | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pharmacokinetics and probability of target attainment for micafungin in normal-weight and morbidly obese adults

Author(s) -

Roeland E. Wasmann,

Cornelis Smit,

Rob ter Heine,

Simon E. Koele,

Eric P H van Dongen,

René M J Wiezer,

David M. Burger,

Catherijne A. J. Knibbe,

Roger J. M. Brüggemann

Publication year - 2018

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dky554

Subject(s) - micafungin , pharmacokinetics , dosing , echinocandin , medicine , pharmacodynamics , population , pharmacology , antifungal , amphotericin b , fluconazole , environmental health , dermatology

The rising pandemic of obesity means an increasing number of obese patients who require antimicrobial therapy for serious infections. Micafungin is an echinocandin drug frequently used as therapy or prophylaxis for fungal infections, predominantly with Candida species. In order to maximize the efficacy of micafungin in obese patients, the dose that corresponds to optimal exposure for each obese individual needs to be identified.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research